UNSPSC 51284137: Cefpimizole sodium

This classification denotes a cephalosporin antibiotic with the molecular formula C28H24N6O10S2.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X4628IMC52, chemically known as 1-(((6r,7r)-2-carboxy-7-((r)-2-(5-carboxyimidazole-4-carboxamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-4-(2-sulfoethyl)pyridinium hydroxide, inner salt, monosodium salt but more generally known as cefpimizole sodium, which bears US NIH Compound Identifier 55324.

UNSPSC 51284137 Cefpimizole sodium, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The source records four recent opportunities tagged to this code, but only one—the Seminole County naloxone and drug deactivation systems procurement—names a product (naloxone) that is a pharmaceutical or pharmaceutical-adjacent consumable. The other three opportunities (Texas HHS direct-to-manufacturer prescription program RFI, City of Tampa medical and first aid supplies for the Fire Department, and Minnesota MMCAP multi-source generic pharmaceuticals RFP) are all pharmaceutical or medical-supply-adjacent procurements, but none specifically solicits cefpimizole sodium or antibiotic products. When recent opportunities diverge significantly from the abstract code name, the mismatch signals either misclassification in the source data or a code that sees little transactional volume relative to its nominal scope. The code shows activity across state health agencies (Texas HHS), county health departments (Seminole County, Florida), municipal fire and rescue departments (City of Tampa), and cooperative purchasing alliances (Minnesota MMCAP), but the opportunities are generalist medical-supply and pharmaceutical-procurement vehicles rather than targeted acquisitions of cefpimizole sodium itself.

The geographic spread of recent activity spans Florida, Texas, Minnesota, and Oregon through MMCAP, with no evidence of concentration in any single state or region. Representative recent opportunities include Seminole County's IFB60459723LAS (naloxone and drug deactivation systems, due July 26, 2023, with quarterly deliveries to Sanford), the City of Tampa's 26P00145 (medical and first aid supplies for the Fire Department Rescue Division, IFB due March 13, 2026, with an estimated $700,000 contract value and sheltered-market set-aside for certified Small Local Business Enterprises), and Minnesota MMCAP's S1070000015802 (generic multi-source pharmaceuticals and OTC products RFP, due March 26, 2026, through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson). The Texas HHS RFI (posted April 3, 2026) is exploratory market intelligence on direct-to-manufacturer prescription programs and does not represent a transactional opportunity. No recent opportunities explicitly name cefpimizole sodium or target antibiotic acquisitions, limiting the code's apparent relevance to current state and local demand.